IAP15 RELIEPCT/PTO 18 JAN 2007

PTC-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES 1089.0600000/MAC/DJN DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/596,945 **CONCERNING A SUBMISSION UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. PCT/JP2004/018643 INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED 14 December 2004 6 January 2004 TITLE OF INVENTION Preventive Agent for Carcinogenesis of Liver Cancer Containing Quinone-Based Compound as Active Ingredient (as amended) APPLICANT(S) FOR DO/EO/US Susumu SHIOMI Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13 A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. 16. L A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4), 19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007, OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/596,945			PCT/JP200		1089.0600000/MAC/DJN	
Form PTO/SB		6 documents	(US1-US2 and FP1- ents FP1-FP4 and NF			documents
The following fees have been submitted					CALCULATIONS	PTO USE ONLY
21. Basic	national fee (37	\$				
22. Exami	ination fee (37 CF					
If the written opinion by IPEA/L All other situation	JS indicates all cla	\$				
If the written opinion IPEA/US i Search fee (37 CF Internation International Search	indicates all claim R 1.445(a)(2)) ha nal Searching Aut ch Report prepara communicated to	\$				
-	TOTAL OF 21, 22	and 22 =	· · · · · · · · · · · · · · · · · · ·			
Additional fee sequence electronic	for specification listing in complia medium) (37 CFI \$250 for each ad					
Total Sheets	Extra Sheets		additional 50 or fraction up to a whole number)			
- 100 =	/50 = 1			× \$250	\$	
Surcharge of \$130 after the date of co		\$				
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$	
Total claims		- 20 =		× \$50	\$	
Independent claim	claims			× \$200	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360	\$	
		\$				
Applicant clair	ms small entity st					
	•		•	SUBTOTAL =	\$	
Processing fee of claimed priority da		\$				
		\$				
Fee for recording by an appropriate		\$				
		\$				
					Amount to be refunded:	\$
					Amount to be charged	\$

PTO-1390 (Rev.'07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. A check in t	he amount of \$	to cover the above fees is enclosed.			
b. Please char A duplicate	ge my Deposit Account Nocopy of this sheet is enclosed.	_ in the amount of \$ to cover the above fees.			
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0036</u> . A duplicate copy of this sheet is enclosed.				
	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
SEND ALL CORRESI	PONDENCE TO:	QA			
CATCAGO ALED	NTD (DED. 04111	SIGNATURE			
CUSTOMER	NUMBER 26111	Daniel J. Nevrivy NAME			
		59,118			
İ		REGISTRATION NUMBER			
		·			

620,063